Design Therapeutics Announces Start Of Friedreich Ataxia Patient Dosing Ex-U.S. In Its Restore-Fa Phase 1/2 Multiple-Ascending Dose Trial Of Dt-216P2
Design Therapeutics Inc DSGN.O:
DESIGN THERAPEUTICS ANNOUNCES START OF FRIEDREICH ATAXIA PATIENT DOSING EX-U.S. IN ITS RESTORE-FA PHASE 1/2 MULTIPLE-ASCENDING DOSE TRIAL OF DT-216P2
DESIGN THERAPEUTICS INC - FDA PLACES CLINICAL HOLD ON IND APPLICATION FOR U.S. SITES
DESIGN THERAPEUTICS INC - NO ADVERSE EVENTS REPORTED IN DT-216P2 ADMINISTRATION
DESIGN THERAPEUTICS INC - PHASE 1 SINGLE-ASCENDING DOSE TRIAL SHOWS DT-216P2 WELL-TOLERATED
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Netflix Q1 2026 Earnings Preview: After Acquisition Turmoil, Where Is This Streaming Giant’s Growth Confidence?

Why AMD Stock Popped: 12-Day Winning Rally Signals CPU Renaissance in Agentic AI Push

Why Is Ethereum Stalling While Bitcoin Surges? Will It Ever Reach $10,000?

APLD Stock Surge: How CoreWeave Lease Amendments and Delta Forge 1 Milestones De-risk the Bull Case

GPT-Rosalind Sparks CRO Sector Slump: Should Investors Buy the Dip or Exit Amid AI Drug R&D Impact?

Tradingkey








